Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire

被引:4
|
作者
Meazza, Raffaella [1 ]
Ruggeri, Loredana [2 ]
Guolo, Fabio [3 ,4 ]
Minetto, Paola [4 ]
Canevali, Paolo [1 ]
Loiacono, Fabrizio [1 ]
Ciardelli, Sara [2 ]
Bo, Alessandra [5 ]
Luchetti, Silvia [5 ]
Serio, Alberto [5 ]
Zannoni, Letizia [6 ]
Retiere, Christelle [7 ]
Colomar-Carando, Natalia [1 ]
Parisi, Sarah [8 ]
Curti, Antonio [8 ]
Lemoli, Roberto M. M. [3 ,4 ]
Pende, Daniela [1 ]
机构
[1] IRCCS Osped Policlin San Martino, Unita Operativa UO Immunol, Genoa, Italy
[2] Univ Perugia, Osped St Maria Misericordia, Dipartimento Med, Div Ematol & Immunol Clin, Perugia, Italy
[3] Univ Genoa, Dipartimento Med Interna DiMI, Clin Ematol, Genoa, Italy
[4] IRCCS Osped Policlin San Martino, Dipartimento Ematol & Oncol, Genoa, Italy
[5] IRCCS Osped Policlin San Martino, Lab Ctr Cellule Staminali & Terapie Cellulari, Genoa, Italy
[6] Univ Bologna, Dipartimento Med Specialist Diagnost & Sperimental, Bologna, Italy
[7] Univ Nantes, Inst Natl St & Rech Medicale INSERM, Ctr Natl Rech Sci CNRS, Ctr Rech Cance rol & Immunol Integree Nantes Anger, Nantes, France
[8] Univ Bologna, Ist Ematol Seragnoli, IRCCS Azienda Ospedaliero, Bologna, Italy
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
基金
欧盟地平线“2020”;
关键词
natural killer cells (NK cells); donor selection; NK alloreactivity; killer immunoglobulin-like receptors (KIR); human leucocyte antigen (HLA); adoptive immunotherapy; acute myeloid leukemia (AML); ACUTE MYELOID-LEUKEMIA; CLASS-I MOLECULES; NATURAL-KILLER-CELLS; INHIBITORY RECEPTOR; MHC MOLECULES; MISSING SELF; KIR; KIR3DL1; DIVERSITY; ALLELES;
D O I
10.3389/fimmu.2023.1111419
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Natural killer (NK) cell-based adoptive immunotherapy in leukemia patients is an emerging field of interest based on clinical evidence of efficacy and safety. Elderly acute myeloid leukemia (AML) patients have been successfully treated with NK cells from HLA-haploidentical donors, especially when high amounts of alloreactive NK cells were infused. The aim of this study was comparing two approaches to define the size of alloreactive NK cells in haploidentical donors for AML patients recruited in two clinical trials with the acronym "NK-AML" (NCT03955848), and "MRD-NK". The standard methodology was based on the frequency of NK cell clones capable of lysing the related patient-derived cells. The alternative approach consisted of the phenotypic identification of freshly derived NK cells expressing, as inhibitory receptors, only the inhibitory KIR(s) specific for the mismatched KIR-Ligand(s) (HLA-C1, HLA-C2, HLA-Bw4). However, in KIR2DS2(+) donors and HLA-C1(+) patients, the unavailability of reagents staining only the inhibitory counterpart (KIR2DL2/L3) may lead to an underestimated identification of the alloreactive NK cell subset. Conversely, in the case of HLA-C1 mismatch, the alloreactive NK cell subset could be overestimated due to the ability of KIR2DL2/L3 to recognize with low-affinity also HLA-C2. Especially in this context, the additional exclusion of LIR1-expressing cells might be relevant to refine the size of the alloreactive NK cell subset. We could also associate degranulation assays, using as effector cells IL-2 activated donor peripheral blood mononuclear cells (PBMC) or NK cells upon co-culture with the related patient target cells. The donor alloreactive NK cell subset always displayed the highest functional activity, confirming its identification accuracy by flow cytometry. Despite the phenotypic limitations and considering the proposed corrective actions, a good correlation was shown by the comparison of the two investigated approaches. In addition, the characterization of receptor expression on a fraction of NK cell clones revealed expected but also few unexpected patterns. Thus, in most instances, the quantification of phenotypically defined alloreactive NK cells from PBMC can provide data similar to the analysis of lytic clones, with several advantages, such as a shorter time to achieve the results and, perhaps, higher reproducibility/feasibility in many laboratories.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients
    Curti, Antonio
    Ruggeri, Loredana
    Parisi, Sarah
    Bontadini, Andrea
    Dan, Elisa
    Motta, Maria Rosa
    Rizzi, Simonetta
    Trabanelli, Sara
    Ocadlikova, Darina
    Lecciso, Mariangela
    Giudice, Valeria
    Fruet, Fiorenza
    Urbani, Elena
    Papayannidis, Cristina
    Martinelli, Giovanni
    Bandini, Giuseppe
    Bonifazi, Francesca
    Lewis, Russell E.
    Cavo, Michele
    Velardi, Andrea
    Lemoli, Roberto M.
    CLINICAL CANCER RESEARCH, 2016, 22 (08) : 1914 - 1921
  • [2] Ex vivo expansion of functional alloreactive NK cells for NK cell-based immunotherapy
    Wieten, Lotte
    Rohrbeck, Leona
    Frings, Peter W. H.
    van Gelder, Michel
    Schellekens, Jennifer
    Germeraad, Wilfred T. V.
    Voorter, Christina E. M.
    Bos, Gerard M. J.
    Tilanus, Marcel G. J.
    TISSUE ANTIGENS, 2010, 75 (05): : 468 - 468
  • [3] The size of the alloreactive NK cell subset:: Implications for donor selection in allogeneic stem cell transplantation
    Andersson, Sandra
    Fauriat, Cyril
    Bjorklund, Andreas
    Carlsten, Mattias
    Schaffer, Marie
    Bjorkstrom, Niklas K.
    Baumann, Bettina C.
    Ljunggren, Hans-Gustaf
    Malmberg, Karl-Johan
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2008, 68 (02) : 223 - 223
  • [4] The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy
    Abakushina, Elena V.
    Popova, Liubov I.
    Zamyatnin, Andrey A., Jr.
    Werner, Jens
    Mikhailovsky, Nikolay V.
    Bazhin, Alexandr V.
    VACCINES, 2021, 9 (11)
  • [5] Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters
    Parisi, Sarah
    Ruggeri, Loredana
    Dan, Elisa
    Rizzi, Simonetta
    Sinigaglia, Barbara
    Ocadlikova, Darina
    Bontadini, Andrea
    Giudice, Valeria
    Urbani, Elena
    Ciardelli, Sara
    Sartor, Chiara
    Cristiano, Gianluca
    Nanni, Jacopo
    Zannoni, Letizia
    Chirumbolo, Gabriella
    Arpinati, Mario
    Lewis, Russell E.
    Bonifazi, Francesca
    Marconi, Giovanni
    Martinelli, Giovanni
    Papayannidis, Cristina
    Paolini, Stefania
    Velardi, Andrea
    Cavo, Michele
    Lemoli, Roberto M.
    Curti, Antonio
    FRONTIERS IN IMMUNOLOGY, 2022, 12
  • [6] Cryopreservation of NK and T Cells Without DMSO for Adoptive Cell-Based Immunotherapy
    Xue Yao
    Sandro Matosevic
    BioDrugs, 2021, 35 : 529 - 545
  • [7] Cryopreservation of NK and T Cells Without DMSO for Adoptive Cell-Based Immunotherapy
    Yao, Xue
    Matosevic, Sandro
    BIODRUGS, 2021, 35 (05) : 529 - 545
  • [8] Evaluation of Interaction Between NK Cells and Colorectal Carcinoma Cells for Development of NK Cell-Based Immunotherapy in Patients with Refractory Disease
    Todisco, Elisabetta
    Turin, Ilaria
    Ferulli, Federica
    Tanzi, Matteo
    Brugnatelli, Silvia
    Delfanti, Sara
    Maestri, Marcello
    Donadon, Matteo
    Cimino, Matteo
    Torzilli, Guido
    Santoro, Armando
    Pedrazzoli, Paolo
    Montagna, Daniela
    BLOOD, 2014, 124 (21)
  • [10] Expansion of Donor NK Cells for Adoptive Immunotherapy in Haploidentical Stem Cell Transplantation: A Phase I-II Study
    Siegler, Uwe
    Meyer-Monard, Sandrine
    Joerger, Simon
    Stern, Martin
    Tichelli, Andre
    Gratwohl, Alois
    Wodnar-Filipowicz, Aleksandra
    Kalberer, Christian
    BLOOD, 2008, 112 (11) : 1327 - 1327